JP2004503581A5 - - Google Patents

Download PDF

Info

Publication number
JP2004503581A5
JP2004503581A5 JP2002511717A JP2002511717A JP2004503581A5 JP 2004503581 A5 JP2004503581 A5 JP 2004503581A5 JP 2002511717 A JP2002511717 A JP 2002511717A JP 2002511717 A JP2002511717 A JP 2002511717A JP 2004503581 A5 JP2004503581 A5 JP 2004503581A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002511717A
Other languages
Japanese (ja)
Other versions
JP2004503581A (ja
Filing date
Publication date
Priority claimed from US09/617,328 external-priority patent/US6458338B1/en
Application filed filed Critical
Publication of JP2004503581A publication Critical patent/JP2004503581A/ja
Publication of JP2004503581A5 publication Critical patent/JP2004503581A5/ja
Pending legal-status Critical Current

Links

JP2002511717A 2000-07-17 2000-12-07 医薬エアゾール製剤 Pending JP2004503581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/617,328 US6458338B1 (en) 1998-09-22 2000-07-17 Amino acid stabilized medicinal aerosol formulations
PCT/US2000/042624 WO2002005784A1 (en) 2000-07-17 2000-12-07 A medicinal aerosol formulation

Publications (2)

Publication Number Publication Date
JP2004503581A JP2004503581A (ja) 2004-02-05
JP2004503581A5 true JP2004503581A5 (OSRAM) 2005-11-17

Family

ID=24473199

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002511717A Pending JP2004503581A (ja) 2000-07-17 2000-12-07 医薬エアゾール製剤

Country Status (7)

Country Link
US (1) US6458338B1 (OSRAM)
EP (1) EP1301173A1 (OSRAM)
JP (1) JP2004503581A (OSRAM)
AU (2) AU2001245190B2 (OSRAM)
CA (1) CA2416403C (OSRAM)
MX (1) MXPA03000442A (OSRAM)
WO (1) WO2002005784A1 (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014870B1 (en) * 1992-11-06 2006-03-21 Greystone Medical Group, Inc. Compositions of oak bark extract related synthetic compositions and method of using same
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20040037898A1 (en) * 1997-10-08 2004-02-26 Hon David N.S Compositions of oak bark extract, related synthetic compositions and method of using same
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
CA2518102C (en) * 2003-03-04 2009-05-12 Tanabe Seiyaku Co., Ltd. Powdery preparation for nasal administration
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20060020035A1 (en) * 2004-03-11 2006-01-26 Oregon Health & Science University Bone marrow protection with N-acetyl-L-cysteine
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
EP1968546A2 (en) * 2005-12-21 2008-09-17 Nitrox, LLC Stables s-nitrosothiol formulations
US20080063722A1 (en) * 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
GB0801876D0 (en) * 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
JP2015512929A (ja) * 2012-04-11 2015-04-30 シプラ・リミテッド 医薬組成物
SI2931713T1 (sl) 2012-12-17 2017-03-31 Parion Sciences, Inc. Derivati kloro-pirazin karboksamida uporabni za zdravljenje bolezni favoriziranih z nezadostno hidracijo sluznice
EP2931712B8 (en) 2012-12-17 2018-05-23 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2015120453A1 (en) * 2014-02-10 2015-08-13 University Of South Florida Hormone treatment for age-related hearing loss-presbycusis
CN106138014A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有糖皮质激素的气雾剂药物组合物
CN106137964A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有丙酸倍氯米松的气雾剂药物组合物
CN106137965A (zh) * 2015-03-25 2016-11-23 天津金耀集团有限公司 一种含有环索奈德的气雾剂药物组合物
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
MX2020000577A (es) * 2017-07-20 2020-09-10 Aztherapies Inc Formulaciones en polvo de cromolina sodica e ibuprofeno.
BR112020002419A2 (pt) 2017-08-14 2020-07-28 Axcella Health Inc. aminoácido para o tratamento de doença do fígado
CN110302157B (zh) * 2018-03-27 2023-01-17 天津金耀集团有限公司 一种异丙托溴铵气雾剂组合物及其制备方法
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
CN110755414A (zh) * 2019-11-12 2020-02-07 南京华盖制药有限公司 一种酒石酸阿福特罗气雾剂及其制备方法
KR102675664B1 (ko) * 2021-09-15 2024-06-17 구주제약주식회사 안정성이 향상된 프로피오닉산 계열 약물 및 안정화제를 포함하는 약학 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (OSRAM) 1956-03-21 1900-01-01
US2885427A (en) 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US4129603A (en) 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
CA1136547A (en) 1979-03-08 1982-11-30 Song-Ling Lin Aerosol anesthetic compositions
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
EP0460064A4 (en) 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
US5376386A (en) 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP1092430B1 (en) 1991-06-10 2003-08-06 Schering Corporation Non-chlorofluorocarbon aerosol formulations
EP0587790B2 (en) 1991-06-10 2000-03-08 Schering Corporation Non-chlorofluorocarbon aerosol formulations
JPH04366411A (ja) 1991-06-13 1992-12-18 Ngk Insulators Ltd 薄膜磁気ヘッド
ATE128350T1 (de) 1991-12-12 1995-10-15 Glaxo Group Ltd Pharmazeutische aerosolformulierung.
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5674471A (en) 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5607662A (en) 1992-03-10 1997-03-04 Fisons, Plc Pharmaceutical inhalation compositions
WO1994021229A1 (en) 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
EP0731688B1 (en) * 1993-12-02 2003-03-05 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
DK0735884T3 (da) 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
SK81197A3 (en) * 1994-12-22 1997-11-05 Astra Ab Aerosol drug formulations, method for production thereof and its use
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5603918A (en) * 1995-06-09 1997-02-18 Boehringer Ingelheim Pharmaceuticals, Inc. Aerosol composition of a salt of ipratropium and a salt of albuterol
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying

Similar Documents

Publication Publication Date Title
JP2001124110A5 (OSRAM)
JP2003510060A5 (OSRAM)
JP2001166649A5 (OSRAM)
JP2004503581A5 (OSRAM)
AU2000236813A8 (OSRAM)
JP2001282648A5 (OSRAM)
JP2000355277A5 (OSRAM)
JP2001263002A5 (OSRAM)
JP2001343880A5 (OSRAM)
JP2002044532A5 (OSRAM)
JP2002148366A5 (OSRAM)
JP2001205817A5 (OSRAM)
JP2002194796A5 (OSRAM)
JP2003505950A5 (OSRAM)
JP2002142162A5 (OSRAM)
JP2001211768A5 (OSRAM)
JP2002183057A5 (OSRAM)
IN192481B (OSRAM)
JP2002007080A5 (OSRAM)
JP2000310635A5 (OSRAM)
JP2002124394A5 (OSRAM)
JP2001198303A5 (OSRAM)
CN3162836S (OSRAM)
CN3141437S (OSRAM)
CN3144928S (OSRAM)